IGC-506

IGC-506 is an investigational small molecule drug candidate being developed by IGC Pharma (formerly India Globalization Capital) for the treatment of Alzheimer's disease. The compound is designed to target the underlying pathology of the disease by inhibiting the aggregation of amyloid-beta (Aβ) peptides, which are central to the formation of neurotoxic plaques in the brain. By preventing the assembly of these toxic aggregates, IGC-506 aims to reduce neuroinflammation and preserve cognitive function, potentially slowing the progression of neurodegeneration. As of late 2023, the drug is in the preclinical stage of development, with studies focusing on its efficacy in reducing plaque burden and improving memory in animal models.